Drug | Page 26 of 280 | SpiritIndia.com

Stent :: Drug eluting stents & bare metal stents yield similarly low mortality rates

A network meta-analysis of 38 randomized controlled trials encompassing more than 18,000 patients found that the mortality risks associated with drug-eluting stents and bare-metal stents are similarly low. This analysis, the largest of its kind to date comparing drug-eluting stents (the CYPHER® Sirolimus-eluting Coronary Stent and the Taxus Stent) to bare-metal stents, appears this week in the medical journal The Lancet.

Blood :: FDA Licenses 15 New Blood Typing Tests

The U.S. Food and Drug Administration licensed 15 new blood typing tests that were previously unavailable in the United States.

Gene :: U. Iowa team identifies genes that improve survival in mice with ALS

University of Iowa researchers investigating the basic biology of cell signaling have made a discovery that may have therapeutic implications for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Heart Attack :: New WHO pocket-charts to identify heart attack & stroke risk

A new book of pocket-charts that will help health workers to identify people at risk of heart attacks and strokes and save lives by prescribing the most appropriate treatment is published by the World Health Organization (WHO).

Pregnancy :: Researchers test old drug with new hopes for pre-eclampsia cure

Researchers at the University of Texas Medical Branch at Galveston are trying to determine whether a drug already available to heart patients can also be used to delay delivery in expectant mothers with severe pre-eclampsia. If so, this groundbreaking study would give hope to hundreds of thousands of women who experience this life-threatening disorder each year.

Breast Cancer :: FDA approves Evista to reduce breast cancer risk in postmenopausal women

The U.S. Food and Drug Administration approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

Blood Pressure :: Genes and drugs team up to lower blood pressure

Patients with high blood pressure respond very differently to anti-hypertensive medication, making treatment selection tricky for physicians. But new research published in the online open access journal, BMC Medical Genetics, pinpoints a number of gene-drug interactions that could allow medication to be tailored to individual patients based on their genetics.

Cancer Pain :: Cephalon reinforces Fentora”s prescribing & dosing information

Cephalon, Inc. (Nasdaq: CEPH) communicated with healthcare professionals to clarify the appropriate patient selection, dosing and administration for FENTORA(R) (fentanyl buccal tablet) [C-II].

Heart :: FDA recommends Bayer”s Trasylol for continued sale in US

The Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to the U.S. Food and Drug Administration (FDA) held a meeting to discuss the risk /benefit profile of Trasylol(R) (aprotinin injection), a Bayer drug used in coronary artery bypass graft (CABG) surgery.

Bipolar Disorder :: Bipolar disorder benefits from breast cancer drug Tamoxifen

The medication tamoxifen, best known as a treatment for breast cancer, dramatically reduces symptoms of the manic phase of bipolar disorder more quickly than many standard medications for the mental illness, a new study shows.